[A26-101] Elinzanetant (vasomotor symptoms in menopause) – Addendum to Project A26-34
Last updated 01.10.2026
Project no.:
A26-101
Commission:
Commission awarded on 11.08.2026 by the Federal Joint Committee (GBA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Reproductive health and birth
Indication:
Patients with moderate to severe vasomotor symptoms associated with the menopause
Result of dossier assessment:
- Patients for whom hormone replacement therapy is an option and who have decided in favour of hormone replacement therapy after an individual risk-benefit assessment: unchanged after addendum: added benefit not proven
- Patients for whom hormone replacement therapy is not an option or who have decided against hormone replacement therapy after an individual risk-benefit assessment: unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-101_V1.1
| Project no. | Title | Status |
|---|---|---|
| A26-34 | Elinzanetant (vasomotor symptoms in menopause) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (GBA)
01-10-2026 A G-BA decision was published.
GBA documents on this decision